U.S., Dec. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07303881) titled 'Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer' on Dec. 12.
Brief Summary: This study is a single-arm clinical trial designed to evaluate the safety and efficacy of golidocitinib in patients with refractory, immune-related hematologic toxicity in advanced lung cancer.
Study Start Date: Feb., 2026
Study Type: INTERVENTIONAL
Condition:
IrAE
Hematologic Disorder
Lung Cancer (Locally Advanced or Metastatic)
Intervention:
DRUG: golidocitinib
Golidocitinib treatment can be discontinued once clinical remission is achieved, with a maximum maintenance period of 12 weeks.
Recruitment Status:...